top of page
Resistance is futile
Resistance is futile
One platform.
The broadest market of any antimicrobial ever developed.
The same resistance mechanism that defeats antibiotics drives biofilm fouling in shipping, disrupts industrial bioprocesses and destabilises agricultural systems. NeoX™ works with one mechanism across multiple compounding markets, and multiple licensing pathways already in motion.
Become an AMR champion
.png)
Financial Investors
Rare category-defining, feasible, deep science with exceptional market pull and regulatory collaboration. Short-, mid- and long-term growth.
.png)
Strategic Partners
Pharma, industrial, food, fast moving consumer products or agribusiness organisations seeking antimicrobial resistance-breaking and antifoul technologies to integrate, licence or co-develop.
.png)
Global health and non-dilutive
Public health organisations, regulatory agencies, stakeholders seeking to minimise the risk of AMR to GDP and humanity. Grant bodies seeking to actively close the pipeline gap and drive equitable health the world over.
Express interest
bottom of page